<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00316381</url>
  </required_header>
  <id_info>
    <org_study_id>REGENT</org_study_id>
    <secondary_id>Grant PBZ-KBN-099/P05/2003</secondary_id>
    <nct_id>NCT00316381</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy to Improve Myocardial Function in Patients With Acute Myocardial Infarction</brief_title>
  <official_title>Myocardial REGeneration by Intracoronary Infusion of Selected Population of stEm Cells in Acute Myocardial iNfarcTion. Randomized Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Silesian School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Higher Education, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Silesian School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the efficiency of a sorted subpopulation of
      CD34+/CXCR4+ cells and unselected bone marrow-derived progenitor cells in the treatment of
      patients with acute myocardial infarction and a low left ventricular ejection fraction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim is to compare the efficiency of sorted subpopulation of CD34+/CXCR4+ cells and unselected
      bone-marrow-derived progenitor cells in treatment of patients with acute myocardial
      infarction and low left ventricular ejection fraction. The subpopulation of CD34+/CXCR4+
      cells most likely contains the tissue-specific stem cells likely to be involved in myocardial
      salvage/regeneration after ischemic injury. This approach is novel and original, because so
      far no study identified the type of cells that actually contribute to stem cell-induced
      improvement in myocardial function in patients with AMI which were treated with unselected
      population of cells. The REGENT trial (prospective, randomized, multicentre trial comparing
      unselected BM mononuclear cells and sorted CD34/CXCR4+ cells in patients with myocardial
      infarction and low left ventricular ejection fraction) successfully treated with primary
      percutaneous coronary angioplasty within 12 hours after the onset of chest pain. The cells
      are delivered by intracoronary infusion. Efficiency is assessed by cardiac magnetic resonance
      imaging, echocardiography and left ventricular angiography.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction and volumes measured by echocardiography</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular ejection fraction and volumes measured by angiography</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>6, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular function in dobutamine stress test</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary flow reserve by adenosine MRI test</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous bone marrow-derived stem cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myocardial infarction treated successfully with primary coronary angioplasty

          -  Left ventricular ejection fraction less than 40%

          -  Informed consent granted

        Exclusion Criteria:

          -  Presence of significant coronary stenoses in non-infarct related artery requiring
             revascularization

          -  Cardiogenic shock

          -  Previous myocardial infarction

          -  Age &lt; 18 years and &gt; 75 years

          -  Pregnancy

          -  Neoplasm

          -  Contraindications for MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michal Tendera, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Division of Cardiology Silesian School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>III Division of Cardiology Silesian School of Medicine</name>
      <address>
        <city>Katowice</city>
        <zip>40-653</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jagiellonian University Institute of Cardiology</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poznan University of Medical Sciences II Clinic of Cardiology</name>
      <address>
        <city>Poznan</city>
        <zip>61-701</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Cardiology</name>
      <address>
        <city>Warszawa</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Wojakowski W, Tendera M, Michałowska A, Majka M, Kucia M, Maślankiewicz K, Wyderka R, Ochała A, Ratajczak MZ. Mobilization of CD34/CXCR4+, CD34/CD117+, c-met+ stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction. Circulation. 2004 Nov 16;110(20):3213-20. Epub 2004 Nov 8.</citation>
    <PMID>15533859</PMID>
  </reference>
  <reference>
    <citation>Wojakowski W, Tendera M, Zebzda A, Michalowska A, Majka M, Kucia M, Maslankiewicz K, Wyderka R, Król M, Ochala A, Kozakiewicz K, Ratajczak MZ. Mobilization of CD34(+), CD117(+), CXCR4(+), c-met(+) stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction. Eur Heart J. 2006 Feb;27(3):283-9. Epub 2005 Nov 2.</citation>
    <PMID>16267071</PMID>
  </reference>
  <reference>
    <citation>Kucia M, Ratajczak J, Ratajczak MZ. Bone marrow as a source of circulating CXCR4+ tissue-committed stem cells. Biol Cell. 2005 Feb;97(2):133-46. Review.</citation>
    <PMID>15656779</PMID>
  </reference>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2006</study_first_submitted>
  <study_first_submitted_qc>April 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2006</study_first_posted>
  <last_update_submitted>May 20, 2008</last_update_submitted>
  <last_update_submitted_qc>May 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2008</last_update_posted>
  <keyword>stem cells</keyword>
  <keyword>acute myocardial infarction</keyword>
  <keyword>regeneration</keyword>
  <keyword>left ventricular ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

